These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36433709)

  • 1. Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Gao L; Cheng Z; Su B; Su X; Song W; Guo Y; Liao L; Chen X; Li J; Tan X; Xu F; Pang S; Wang K; Ye J; Wang Y; Chen L; Sun J; Ji L
    Diabetes Obes Metab; 2023 Mar; 25(3):785-795. PubMed ID: 36433709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
    Ji L; Jiang X; Hao Q; Cheng Z; Wang K; Pang S; Liu M; Guo Y; Chen X; Su X; Ning T; Liu J; Bian F; Li Y; Zhang Z; Song W; Sun J
    Diabetes Obes Metab; 2023 May; 25(5):1229-1240. PubMed ID: 36594724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
    Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Guo L; Tian F; Liu L; Chen M; Jiang C; Li S; Liu C; Zhang Y; Qin J; Yu D; Zong Y; Dai W
    Diabetes Obes Metab; 2024 Jul; 26(7):2830-2838. PubMed ID: 38602409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
    Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
    Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
    Wang Y; Jiang C; Dong X; Chen M; Gu Q; Zhang L; Fu Y; Pan T; Bi Y; Song W; Xu J; Lu W; Sun X; Ye Z; Zhang D; Peng L; Lin X; Dai W; Wang Q; Yang W
    Diabetes Obes Metab; 2024 Jul; 26(7):2774-2786. PubMed ID: 38618970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.
    Xu J; Ling H; Geng J; ; Huang Y; Xie Y; Zheng H; Niu H; Zhang T; Yuan J; Xiao X
    Diabetes Obes Metab; 2022 Nov; 24(11):2232-2240. PubMed ID: 35791646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
    Kwak SH; Han KA; Kim KS; Yu JM; Kim E; Won JC; Kang JG; Chung CH; Oh S; Choi SH; Won KC; Kim SG; Cho SA; Cho BY; Park KS
    Diabetes Obes Metab; 2023 Jul; 25(7):1865-1873. PubMed ID: 36872067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
    Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
    Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
    BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
    Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
    Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.